Form 4: AVITA Medical Director Lou Panaccio Reports Significant Equity Compensation Awards

AVITA Medical, Inc. Director Lou Panaccio has reported the acquisition of 10,022 restricted stock units and 4,295 stock options as part of his compensation, following stockholder approval.

Summary

• Lou Panaccio, a Director of AVITA Medical, Inc. (RCEL), reported changes in his beneficial ownership through a Form 4 filing.
• On January 21, 2025, Mr. Panaccio was granted 10,022 restricted stock units (RSUs) and 4,295 stock options.
• The RSUs represent a contingent right to be issued one share of Common Stock each and are subject to time-based vesting, scheduled to vest 12 months after the grant date.
• The stock options have an exercise price of $8.73 per share, which was the closing price of Common Stock on Nasdaq on the grant date.
• These options become exercisable on January 21, 2026, and have an expiration date of January 21, 2035.
• Both the RSU and option grants were contingent on stockholder approval, which was obtained on June 4, 2025.
• Following these transactions, Mr. Panaccio directly beneficially owns 56,428 shares of Common Stock, which includes unvested RSUs, and 4,295 stock options.
• Additionally, he indirectly beneficially owns 5,972 shares of Common Stock, which translate from 29,860 CDIs held by The Panaccio Superannuation Fund.

Sentiment

Score: 6

Explanation: Slightly positive. The document details a director receiving equity compensation, which generally aligns their interests with shareholders. It is a routine disclosure for insider transactions and does not reflect operational performance or significant new developments.

Positives

• The equity compensation awards to a director, Lou Panaccio, enhance the alignment of his interests with those of the company's shareholders.
• The grants received stockholder approval on June 4, 2025, indicating shareholder support for the director's compensation structure.

Future Outlook

The document primarily details past equity compensation grants and their subsequent stockholder approval. The future outlook is limited to the vesting of the 10,022 RSUs 12 months after the grant date (January 21, 2026) and the exercisability of the 4,295 stock options from the same date until their expiration in 2035.

Industry Context

This Form 4 filing reflects a routine disclosure of equity compensation for a non-executive director, a common practice across publicly traded companies to align management and board interests with long-term shareholder value. It does not provide broader industry trends or competitive analysis specific to AVITA Medical's sector.

Comparison to Industry Standards

• The compensation structure involving Restricted Stock Units (RSUs) and stock options with time-based vesting and an exercise price set at market value is a standard and widely accepted practice for compensating non-executive directors in publicly traded companies.
• This approach is consistent with corporate governance best practices aimed at aligning director incentives with long-term company performance and shareholder returns, commonly observed in the medical technology and biotechnology industries.

Corporate Governance

Related Party Transactions

• Lou Panaccio indirectly beneficially owns 5,972 shares of Common Stock (translating from 29,860 CDIs) held by The Panaccio Superannuation Fund. Mr. Panaccio is a director of Tercus Pty Ltd, the trustee of the Fund, and a beneficiary of the Fund, and may be deemed to have shared voting and dispositive power over these CDIs.

Stakeholder Impact

• Shareholders: The equity compensation granted to a director is intended to align their interests with those of the shareholders, potentially leading to more shareholder-centric decision-making and long-term value creation.

Next Steps

• The 10,022 Restricted Stock Units (RSUs) granted to Lou Panaccio are scheduled to vest on January 21, 2026.
• The 4,295 stock options granted will become exercisable on January 21, 2026.

Key Dates

Keywords

AVITA Medical, RCEL, Form 4, SEC Filing, Insider Trading, Beneficial Ownership, Restricted Stock Units, Stock Options, Director Compensation, Equity Compensation